Boehringer Ingelheim leads €9m series-A for Heparegenix

According to a statement, the series-A round will provide funding for the ongoing medical discovery programme, as well as the pre-clinical development of drug candidates. In 2019, the company aims to deliver the first clinical study for its treatment of acute liver failure.

Boehringer Ingelheim led the funding round through its 2010-vintage Boehringer Ingelheim Venture Fund, alongside Novo Seeds, the early-stage investment arm of Novo, the asset management firm owned by Novo Nordisk Foundation. German research business Ascenion provided additional capital to support the acquisition of the exclusive IP rights.

Company
Founded in 2015, Heparegenix develops a therapeutic treatment for liver diseases focusing on regulating the regenerative capacity of hepatocytes through a mitogen-activated protein. The early-stage business is based at the University Hospital Tubingen, in Germany.

People
Boehringer Ingelheim – Dettlev Mennerich (investment director).
High-Tech Gründerfonds – Frank Hensel (investment manager).
Heparegenix – Wolfgang Albrecht (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• DACH
• Venture
• Germany
• High-Tech Gründerfonds